title: Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy.
abstract: The effect of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematologic parameters was evaluated in a phase I clinical study in 18 patients with advanced malignancy. G-CSF was administered once daily as a 30-minute infusion for 14 days; three patients each were treated at increasing dose levels of 1, 3, 10, 30, and 60 micrograms kg-1 day-1. A transient decrease in neutrophil and monocyte counts was observed immediately after the G-CSF infusion, followed by a dose-dependent increase of up to 15-fold. G-CSF-induced neutrophils exhibited an increased O2- radical production, and serum levels of enzymes related to granulocyte turnover, including lysozyme and elastase, were markedly elevated during therapy. A dose-dependent depression of platelet counts occurred in the second third of the treatment course, followed by a spontaneous recovery despite continuing therapy. G-CSF was well-tolerated; minor to moderate bone pain was the most common side effect. The primary course of the malignant diseases studied was not significantly altered. G-CSF appears to be an appropriate means to selectively increase the number of functionally competent polymorphonuclear phagocytes.
authors: Department of Hematology, University of Mainz, FRG.
authors: A
authors: A
authors: Lindemann
authors: F
authors: F
authors: Herrmann
authors: W
authors: W
authors: Oster
authors: G
authors: G
authors: Haffner
authors: W
authors: W
authors: Meyenburg
authors: L M
authors: LM
authors: Souza
authors: R
authors: R
authors: Mertelsmann
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D001792:Blood Platelets / Q000378:metabolism; D003115:Colony-Stimulating Factors / Q000009:adverse effects / Q000494:pharmacology*; D004341:Drug Evaluation; D016179:Granulocyte Colony-Stimulating Factor; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D011994:Recombinant Proteins; D013481:Superoxides / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors; D010980:Platelet Membrane Glycoproteins; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D013481:Superoxides; D016179:Granulocyte Colony-Stimulating Factor